Tecartus

Tecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor unless ineligible to BTK inhibitorLimitation of use: Tecartus is not indicated for the treatment of patients with active central nervous system lymphoTecartus is indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia  ALLFor further information and full list of adverse events, please refer to the approved prescribing informationas available at Israeli Ministry of Health website: https://israeldrugs.health.gov.il/#!/byDrug

Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form at https://sideeffects.health.gov.il

Report an AE: https://www.gileadisrael.co.il/utility/contact 

For any further questions please contact:
medinfo.israel@gilead.com

Gilead Sciences Israel Ltd. All rights reserved©

IL-TEC-0275, MAY 2025